Fig. 1 · Structure

Documents & Downloads

Xevinapant (AT-406, SM-406, ARRY-334543)

Cat. No. A11163 CAS 1071992-99-8

IAP inhibitor

AT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP).

In Stock

Publications for Xevinapant

2 publications citing this product

  1. Yoshikawa M, .et al. , J Med Chem, 2018, Mar 22;61(6):2384-2409 PMID: 29485864
  2. Tsuyoshi Ishii, .et al. , Sci Rep, 2017, 7: 13000 PMID: 29026104

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SM-406/AT-406 binds the BIR3 domains of XIAP, cIAP1 and cIAP2. Competitive fluorescence-polarization assays reported Ki values of 66.4 ± 9.7, 1.9 ± 0.2 and 5.1 ± 0.4 nM, respectively (figure labels: Ki ± SD). These values describe the paper’s compound 2; its synthesis reports a TFA salt, and exact assay-form equivalence to the catalog material was not established. [1]

In a cell-free caspase-9 assay, 1 μM SM-406 restored activity suppressed by 500 nM XIAP BIR3. The inactive analogue SM-428 failed to restore activity at 100 μM, supporting functional XIAP antagonism in this system. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
cIAP1 Ki 1.9 nM
cIAP2 Ki 5.1 nM
XIAP Ki 66.4 nM

Cellular Effect

Cell Line Activity Value Description Reference
EVSA-T EC50 0.0021 μM Cytotoxicity against human sensitive EVSA-T cells assessed as inhibition of cell growth after 72 hrs by Alamar Blue assay [PMID: 26218264]
HCT-116 EC50 > 10 μM Cytotoxicity against human insensitive HCT116 cells assessed as inhibition of cell growth after 72 hrs by Alamar Blue assay [PMID: 26218264]
HEK293 EC50 0.034 μM Antagonist activity at full-length FLAG-tagged XIAP (unknown origin) transfected in HEK293 cells assessed as inhibition of interaction with caspase 9 after 2 hrs by immunoprecipitation assay [PMID: 26218264]
MDA-MB-231 EC50 0.019 μM Cytotoxicity against human sensitive MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by Alamar Blue assay [PMID: 26218264]
MDA-MB-231 IC50 144 nM Growth inhibition of human MDA-MB-231 cells after 4 days by WST8 assay [PMID: 21443232]
SK-OV-3 IC50 142 nM Growth inhibition of human SKOV3 cells after 4 days by WST8 assay [PMID: 21443232]

In Vitro Studies

AT-406 produced heterogeneous responses in an eight-line ovarian cancer panel after 48 h. The authors classified approximately 60% of the lines as sensitive using IC50 <10 μg/ml; several lines remained relatively insensitive. Salt form was not specified, and these mass-based results were not converted to molar potency. [2]

Binding to three IAP BIR3 domains

Biochemical assay · Recombinant human XIAP, cIAP1 and cIAP2 BIR3 domains [1]

Competitive tracer displacement showed stronger binding to cIAP1/cIAP2 than to XIAP. Smac AVPI peptide and inactive analogue 3 (SM-428) were comparators.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
XIAP BIR3 bindingKi ± SD 66.4 ± 9.7 nM[1]
cIAP1 BIR3 bindingKi ± SD 1.9 ± 0.2 nM[1]
cIAP2 BIR3 bindingKi ± SD 5.1 ± 0.4 nM[1]
Comparator bindingReported Ki Smac AVPI: XIAP 3.6 μM; cIAP1 184 nM; cIAP2 316 nM. Compound 3 showed minimal binding at 10 μM.[1]

Literature-Reported Treatment Conditions

Exposure duration
2–3 h incubation before competitive-FP measurements
Method
Competitive fluorescence polarization with fluorescent analogue 5; Ki calculated from fitted IC50.
Reported limits
Assay subsection does not separately identify counterion or salt correction; compound concentration series not transcribed.
Methods and source locations

Compound reported in the paper: SM-406 / AT-406; Compound label in the paper: Compound 2

Reported compound-2 binding constants; no salt conversion or product-lot potency claim.

Figure 4A–C; binding-results paragraph; Experimental Section, fluorescence-polarization assays; Figure 1 and compound-2 characterization

XIAP BIR3 binding: Competitive FP; figure labels Ki ± SD and states three independent experiments for the IC50 SD. Ki is derived from IC50, not a treatment concentration. — Figure 4A embedded legend; caption; competitive-FP methods

cIAP1 BIR3 binding: Competitive FP; figure labels Ki ± SD and states three independent experiments for the IC50 SD. Ki is derived from IC50, not a treatment concentration. — Figure 4B embedded legend; caption; competitive-FP methods

cIAP2 BIR3 binding: Competitive FP; figure labels Ki ± SD and states three independent experiments for the IC50 SD. Ki is derived from IC50, not a treatment concentration. — Figure 4C embedded legend; caption; competitive-FP methods

Comparator binding: Same competitive-FP assay; rounded peptide values are from narrative, not curve estimates. — Figure 4A–C and associated results paragraph

Functional antagonism of XIAP BIR3

Biochemical assay · MDA-MB-231 cell lysate with cytochrome c/dATP-activated caspase-9 and added XIAP BIR3 [1]

Compound 2 restored caspase-9 substrate cleavage suppressed by 500 nM XIAP BIR3. This cell-free result supports functional XIAP antagonism, without establishing cellular sensitivity in every model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Restoration of XIAP-suppressed caspase-9 activityQualitative functional response Compound 2 at 1 μM restored activity to the activated-lysate level; compound 3 at 100 μM failed to restore activity.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Compound 2: 0.1, 0.5 and 1 μM in Figure 5; compound 3: 100 μM; XIAP BIR3: 500 nM
Exposure duration
Figure 5 follows substrate cleavage for approximately 1 h; methods state reaction monitored for 1–2 h.
Method
Z-LEHD-AFC substrate-cleavage fluorescence assay
Co-treatment
Cytochrome c and dATP activate caspase-9 in lysates; recombinant XIAP BIR3 inhibits it. These are assay components.
Reported limits
Figure 5 does not report replicate n or error bars. Assay vehicle and separate counterion identity are not specified in this subsection.
Methods and source locations

Compound reported in the paper: SM-406 / AT-406; Compound label in the paper: Compound 2; compound 3 as inactive control

Cell-free XIAP BIR3 antagonism using the reported compound-2 material.

Figure 5 and associated results; Experimental Section, cell-free functional assay

Restoration of XIAP-suppressed caspase-9 activity: Compare cytochrome c/dATP maximum activation, added-XIAP inhibition, compound-2 titration and inactive-analogue controls; no RFU values estimated. — Figure 5 curves/legend and associated results paragraph

Heterogeneous single-agent response in ovarian cancer cells

Cell-based study · Eight human ovarian cancer cell lines: SKOV3ip, SKOV3, OVCAR3ip, OVCAR-4, OVCAR-8, IGROV1, OVCAR-3 and OVCAR-5 (figure labels) [2]

The panel showed sensitive and relatively insensitive cell lines. The authors reported approximately 60% as sensitive at an IC50 threshold below 10 μg/ml; this is a panel-specific result, not a general response rate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-viability response across the ovarian panelAuthor-reported sensitivity threshold Approximately 60% of the tested lines: IC50 <10 μg/ml.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing AT-406 concentrations in μg/ml, with line-specific series plotted in Figure 2A–B; no reconstructed dose series.
Exposure duration
48 h
Method
CellTiter-Glo luminescent cell-viability assay; cells plated in triplicate.
Reported limits
In vitro vehicle, counterion, batch identity and chemical purity are not specified in the read methods. The low-dose IC50 estimates rely on Figure S1, not retrieved and not adopted.
Methods and source locations

Compound reported in the paper: AT-406

Named-compound literature response at reported mass concentrations; no molecular-weight or salt conversion, and no Adooq material validation.

Figure 2A–B; Results, AT-406 displays single agent activity; Materials and Methods, cell viability assays

Cell-viability response across the ovarian panel: 48-h ATP-dependent luminescent viability; Figure 2A–B shows relatively insensitive OVCAR-8, IGROV1 and OVCAR-3 as well as sensitive lines. Zero-dose points are the baseline. Do not interpret ATP signal as a direct cell-count endpoint. — Figure 2A–B and associated results; cell viability methods

In Vivo Studies

In immunocompetent mice bearing mEER tumors, xevinapant (100 mg/kg by oral gavage, 5 days/week for 3 weeks) added to cisplatin and radiotherapy delayed tumor growth and prolonged time to the humane survival endpoint compared with chemoradiotherapy plus vehicle. This was a combination result in a specific tumor model. [3]

In a separate mEER tumor-growth comparison, anti-CD8 treatment reduced chemoradiotherapy-associated tumor control (P = 0.0317), while its effect in the xevinapant combination group was not statistically significant (P = 0.182). The result limits an assumption that improved local control necessarily reflects stronger CD8-mediated immunity; nonsignificance does not establish equivalence or complete CD8 independence. [3]

Xevinapant plus chemoradiotherapy in mEER tumors

Animal study · Female C57BL/6 wild-type mice, 8–14 weeks old, with subcutaneous mEER head-and-neck tumors; 11–12 mice/group in Figure 1B–C [3]

Adding xevinapant to CRT delayed tumor growth and prolonged time to the humane survival endpoint relative to CRT plus vehicle. Vehicle, xevinapant-alone and cisplatin-alone arms were also displayed; no monotherapy efficacy is inferred from the combination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth: CRT plus xevinapant versus CRT plus vehicleP value P = 0.0008[3]
Time to humane survival endpoint: CRT plus xevinapant versus CRT plus vehicleP value P = 0.0298[3]

Conditions shared by the study groups

Vehicle
0.6% malic acid (w/v) in 85 mmol/L sodium acetate buffer, pH 4.5
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CRT plus xevinapant
Xevinapant 100 mg/kg; cisplatin 7 mg/kg; RT 6 Gy × 3
CRT plus vehicleGreater tumor-growth delay and longer time to humane survival endpoint than CRT plus vehicle.[3]
CRT plus vehicle comparator
Cisplatin 7 mg/kg; RT 6 Gy × 3
Vehicle, xevinapant-alone and cisplatin-alone arms also shownCRT alone delayed growth, with less delay and shorter humane-endpoint survival than CRT plus xevinapant.[3]
CRT plus xevinapant
Model: Female C57BL/6 wild-type mice, 8–14 weeks old, with subcutaneous mEER head-and-neck tumors; 11–12 mice/group in Figure 1B–C
Route: Xevinapant: oral gavage; cisplatin: intraperitoneal; RT: localized irradiation
Frequency: Xevinapant: 5 consecutive days/week; RT: alternate days; cisplatin: single dose depicted on day 14 in Figure 1A
Treatment course: Xevinapant: 3 weeks
CRT plus vehicle comparator
Model: Female C57BL/6 wild-type mice, 8–14 weeks old, with subcutaneous mEER head-and-neck tumors; 11–12 mice/group in Figure 1B–C
Route: Cisplatin: intraperitoneal; RT: localized irradiation
Frequency: RT on alternate days; cisplatin single dose depicted in Figure 1A
Treatment course: Comparator followed alongside combination
Methods and source locations

Compound reported in the paper: Xevinapant

Published xevinapant combination experiment in an immunocompetent mouse model; not a product-lot, monotherapy or clinical-efficacy claim.

Figure 1A–C; Results first subsection; Methods, mouse models, in vivo tumor treatments and statistics

Tumor growth: CRT plus xevinapant versus CRT plus vehicle: Tumor-growth AUC comparison; plotted data mean ± SEM. Caption: 11–12 mice/group; representative of ≥2 independent experiments, not a pooled animal count. — Figure 1B (displayed comparison); statistical methods

Time to humane survival endpoint: CRT plus xevinapant versus CRT plus vehicle: Kaplan–Meier/log-rank Mantel–Cox. Euthanasia at any tumor dimension 15 mm or weight loss ≥20% of baseline; this is not unqualified natural survival. — Figure 1C; mouse-model and statistical methods

CRT plus xevinapant · Figure 1A–C; in vivo treatment methods

CRT plus vehicle comparator · Figure 1A–C; in vivo treatment methods

Anti-CD8 treatment modifies CRT response differently with xevinapant

Animal study · mEER tumors in C57BL/6 mice; 11–15 mice/treatment group [3]

An anti-CD8 treatment comparison reduced tumor control in the CRT group but did not significantly change tumor growth in the CRT-plus-xevinapant group. This records the treatment comparison; it does not prove complete CD8 depletion or identify the cause of immune impairment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CRT: anti-CD8 versus isotype tumor growthP value P = 0.0317[3]
CRT plus xevinapant: anti-CD8 versus isotype tumor growthP value P = 0.182[3]

Conditions shared by the study groups

Route
Xevinapant: oral gavage; anti-CD8/isotype: intraperitoneal
Frequency
Xevinapant: 5 consecutive days/week; antibody maintenance twice weekly
Treatment course
Xevinapant 3 weeks; antibody loading 24 h before treatment initiation, total 10 antibody doses per Figure 1 caption
Vehicle
0.6% malic acid (w/v) in 85 mmol/L sodium acetate buffer, pH 4.5
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CRT plus xevinapant, with anti-CD8 versus isotype
Xevinapant 100 mg/kg; anti-CD8 loading 400 μg/mouse, maintenance 200 μg/mouse
Same CRT-plus-xevinapant regimen with isotype antibody; CRT/isotype and CRT/anti-CD8 groups also comparedAnti-CD8 did not significantly alter combination-group tumor growth (P = 0.182); CRT-only comparison showed reduced control (P = 0.0317).[3]
CRT plus xevinapant, with anti-CD8 versus isotype
Model: mEER tumors in C57BL/6 mice; 11–15 mice/treatment group
Reported limits: Direct depletion efficiency not verified from acquired main figure.
Methods and source locations

Compound reported in the paper: Xevinapant

Observed anti-CD8/isotype tumor-growth comparisons in this model; mechanistic independence remains limited.

Figure 1D; caption and first Results subsection; in vivo treatment and statistics methods

CRT: anti-CD8 versus isotype tumor growth: Tumor-growth AUC comparison; anti-CD8 associated with loss of tumor control. Mean ± SEM; 11–15 mice/group, representative of ≥2 independent experiments. — Figure 1D left panel; caption and Results first subsection

CRT plus xevinapant: anti-CD8 versus isotype tumor growth: No statistically significant change in tumor growth under the reported comparison; not evidence of equivalence or a validated zero effect. — Figure 1D right panel; caption and Results first subsection

CRT plus xevinapant, with anti-CD8 versus isotype · Figure 1A,D and caption; in vivo treatment methods

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1071992-99-8
Applications IAP inhibitor
Formula C32H43N5O4
Molecular Weight 561.71
Synonyms AT406; SM-406; ARRY-334543
SMILES
C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (151.32 mM)
Water Insoluble
Ethanol 85 mg/mL (151.32 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Cai Q, Sun H, Peng Y, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. Journal of medicinal chemistry (2011). PMID: 21443232 DOI: 10.1021/jm101505d Source material
  2. [2] Brunckhorst MK, Lerner D, Wang S, et al. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer biology & therapy (2012). PMID: 22669575 DOI: 10.4161/cbt.20563 Source material
  3. [3] Chan Wah Hak C, Patin EC, Patrikeev A, et al. Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer. Cancer research communications (2025). PMID: 41123992 DOI: 10.1158/2767-9764.crc-25-0604 Source material

Publications

2 publications citing this product

  1. Yoshikawa M, .et al. , J Med Chem, 2018, Mar 22;61(6):2384-2409 PMID: 29485864
  2. Tsuyoshi Ishii, .et al. , Sci Rep, 2017, 7: 13000 PMID: 29026104

Added to your cart

View Cart Checkout
Loading...